However, there are some shortcomings in our study, such as the fact that we did not validate the function of CDC25B in a variety of hepatocellular carcinoma cell lines, and we did not validate the results of the biosignature analysis by performing experiments on the signaling pathway mechanisms. This evidence concerns the gene CDC25B and hepatocellular carcinoma.